Search

Displaying results 7141 - 7150 of 10000 in total
  1. Drug

    Galactose-uridine-5'-diphosphate

    go.drugbank.com/drugs/DB03501
    Experimental

    Serves as a source of galactose in the synthesis of lipopolysaccharides, cerebrosides, and lactose.

    Categories: Nucleic Acids, Nucleotides, and Nucleosides
  2. Drug

    AEOL-10150

    go.drugbank.com/drugs/DB05874
    Experimental

    AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.

  3. Drug

    XR5944

    go.drugbank.com/drugs/DB06364
    Experimental

    It has both intercalating and antineoplastic activities.

  4. Drug

    ISIS 14803

    go.drugbank.com/drugs/DB05803
    Investigational

    ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits

  5. Drug

    Sulesomab

    go.drugbank.com/drugs/DB13976
    Approved

    Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.

    Categories: Amino Acids, Peptides, and Proteins, Inflammation and Infection Detection
  6. Drug

    Proxalutamide

    go.drugbank.com/drugs/DB16065
    Investigational

    Proxalutamide is under investigation in clinical trial NCT03899467 (The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer).

  7. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time. … In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro.

  8. Drug

    HY10275

    go.drugbank.com/drugs/DB05079
    Experimental

    HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep. … This dual-acting receptor activity and the lack of affinity for undesired off- target receptors are thought to account for the compounds excellent efficacy and tolerability profile.

  9. Drug

    Alomfilimab

    go.drugbank.com/drugs/DB16681
    Investigational

    Alomfilimab is under investigation in clinical trial NCT03829501 (Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer).

  10. Drug

    Letaxaban

    go.drugbank.com/drugs/DB11984
    Investigational

    Letaxaban has been used in trials studying the treatment and prevention of Venous Thromboembolism and Acute Coronary Syndrome.